Outset Medical (OM) Resumes Shipment of Tablo Systems for Home Use, Reports Second Quarter 2022 Financial Results and Provides 2022 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Outset Medical Inc. (OM) to Resume Trading at 10:30 a.m.
August 1, 2022 10:15 AM EDTOutset Medical Inc. (NASDAQ: OM) to Resume Trading at 10:30 a.m.
Outset Medical Inc. (OM) Misses Q2 EPS by 13c
August 1, 2022 10:04 AM EDTOutset Medical Inc. (NASDAQ: OM) reported Q2 EPS of ($0.77), $0.13 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $25.1 million versus the consensus estimate of $29.22 million.
GUIDANCE:
Outset Medical Inc. sees FY2022 revenue of $105-110 million, versus the... More
Outset Medical Inc. (OM) Halted, News Pending
August 1, 2022 9:37 AM EDTOutset Medical Inc. (NASDAQ: OM) Halted, News Pending
... MoreCowen Reiterates Outperform Rating on Outset Medical Inc. (OM), Comments on FDA Clearance
August 1, 2022 8:58 AM EDTCowen analyst Joshua Jennings reiterated an Outperform rating and $33.00 price target on Outset Medical Inc. (NASDAQ: OM).
The analyst comments "OM Has Received a New 510(k) Clearance for the Tablo Hemodialysis System. In a decision dated July 29, 2022, the FDA cleared a new 510(k)... More
Stifel on Outset Medical Inc. (OM): 'At Last, A Big Sigh of Relief As FDA Terms Tablo Catch-Up Filing As “Substantially-Equivalent”'
August 1, 2022 8:57 AM EDTStifel analyst Rick Wise reiterated a Buy rating and $24.00 price target on Outset Medical Inc. (NASDAQ: OM).
The analyst comments "Last Friday, Outset received a positive FDA update on its Tablo catch-up 510K filing, with the agency providing a substantially-equivalent decision on the filing.... More
Outset Medical Inc. (OM) Gains 6% Premarket; Cowen Cites FDA Clearance - Bloomberg
August 1, 2022 8:55 AM EDTOutset Medical Inc. (NASDAQ: OM) Gains 6% Premarket; Cowen Cites FDA Clearance - Bloomberg
... More